AstraZeneca shares drop 7% after report on $400 billion merger talks with Bristol Myers Squibb

AstraZeneca shares dropped seven percent following a report of merger talks with Bristol Myers Squibb. Per CNBC, the two companies have been discussing a potential deal valued at around four hundred billion dollars over several months.

Listen to this story

Hear this and more stories in a personalized audio briefing.

Open The Chonkerton